Alzamend Neuro Signs $25M Securities Purchase Agreement With Ault Lending; Alzamend Receives $7.5M In Gross Proceeds Form Initial Tranche
Alzamend Neuro, Inc. (Nasdaq: ALZN) ("Alzamend"), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer's disease ("Alzheimer's"), bipolar
Alzamend Neuro got $7.5 million in upfront cash from a larger $25 million financing deal to help fund its Alzheimer's medicine research. When a company raises money this way, it means they have runway to keep working on their drugs, so watch whether their research progress stays on track.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.